API | masitinib

masitinib Report issue

Small molecule Experimental

AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19. ^Wikipedia

Chemistry

SMILES: Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
InChIKey: WJEOLQLKVOPQFV-UHFFFAOYSA-N
Mol. Mass: 498.66
ALogP: 5.26 Partition coefficient
ChEMBL Molecules:

masitinib

masitinib mesylate

More Chemistry

Pharmacology

Mechanisms of Action:
- Fibroblast growth factor receptor 3 (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (21)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (21)

Alzheimer Disease (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Arthritis, Rheumatoid (Phase 2/Phase 3)

Asthma (Phase 3)

Colorectal Neoplasms (Phase 3)

COVID-19 (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Healthy Volunteers (Early Phase 1)

Intestinal Neoplasms (Phase 3)

Mast Cell Activation Syndrome (Phase 2)

Mastocytosis (Phase 2)

Mastocytosis, Systemic (Phase 3)

Melanoma (Phase 3)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 2/Phase 3)

Neoplasms ()

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Psoriasis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 39
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue